Hybribio subsidiary expands product scope with updated manufacturing license

Guangdong Hybribio Biotech Co., Ltd. announced that its wholly-owned subsidiary, Chaozhou Hybribio Biochemical Co., Ltd., has received a revised medical device manufacturing license from the Guangdong Provincial Drug Administration. The amendment primarily concerns changes to the production scope.

The revised license now permits Chaozhou Hybribio Biochemical Co., Ltd. to manufacture III class 6840 in vitro diagnostic reagents, in addition to II class 18 obstetrics and gynecology, assisted reproduction, and contraception devices. This expansion significantly broadens the subsidiary's product offerings in the medical device sector. The company's registered address remains in the North High-tech Zone D5-3-3-4 of Chaozhou Economic Development Zone, with an additional manufacturing address at Floors 4, 5, and 6B of the Hybribio Integrated Building, No. 1 Chuangbei Road, Xiangqiao District, Chaozhou City.

The updated medical device manufacturing license is valid until January 8, 2029. This regulatory update is expected to support Guangdong Hybribio Biotech's strategic goals by allowing its subsidiary to produce a wider range of medical devices and in vitro diagnostic products, enhancing its market position and operational flexibility.